Table 5.
Sub-outcome of logistic regression of risk of CVD.
| N | No. of CVD | Crude OR (95% C.I.) | p -value | Adjusted OR†(95% C.I.) | p -value | |
|---|---|---|---|---|---|---|
| Ischemic heart disease | ||||||
| Adherence rate of allopurinol | ||||||
| None | 2,527 | 451 | Reference | Reference | ||
| <0.3 | 1,761 | 358 | 1.17 (1.01–1.37) | 0.041 | 1.20 (1.00–1.43) | 0.0497 |
| 0.3–0.6 | 170 | 29 | 0.95 (0.63–1.43) | 0.795 | 1.02 (0.66–1.56) | 0.930 |
| ≥0.7 | 93 | 7 | 0.37 (0.17–0.81) | 0.013 | 0.46 (0.21–1.02) | 0.057 |
| Adherence rate of benzbromarone | ||||||
| None | 904 | 152 | Reference | Reference | ||
| <0.3 | 3,076 | 615 | 1.24 (1.02–1.50) | 0.033 | 1.29 (1.02–1.62) | 0.030 |
| 0.3–0.6 | 405 | 64 | 0.93 (0.68–1.28) | 0.649 | 1.02 (0.72–1.45) | 0.891 |
| ≥0.7 | 166 | 14 | 0.46 (0.26–0.81) | 0.007 | 0.51 (0.28–0.93) | 0.028 |
| Cerebrovascular disease | ||||||
| Adherence rate of allopurinol | ||||||
| None | 3,650 | 1,574 | Reference | Reference | ||
| <0.3 | 2,550 | 1,147 | 1.08 (0.97–1.19) | 0.147 | 1.12 (0.99–1.26) | 0.061 |
| 0.3–0.6 | 237 | 96 | 0.90 (0.69–1.17) | 0.431 | 0.93 (0.70–1.22) | 0.593 |
| ≥0.7 | 130 | 44 | 0.67 (0.47–0.98) | 0.037 | 0.71 (0.48–1.05) | 0.083 |
| Adherence rate of benzbromarone | ||||||
| None | 1,298 | 546 | Reference | Reference | ||
| <0.3 | 4,457 | 1,996 | 1.12 (0.99–1.27) | 0.083 | 1.16 (1.00–1.34) | 0.058 |
| 0.3-0.6 | 583 | 242 | 0.98 (0.80–1.19) | 0.821 | 1.00 (0.80–1.24) | 0.977 |
| ≥0.7 | 229 | 77 | 0.70 (0.52–0.94) | 0.017 | 0.71 (0.52–0.97) | 0.034 |
†
Adjusted for allopurinol, benzbromarone, age, sex, hypertension, hyperlipidemia, chronic liver disease, diabetes, COPD, autoimmune disease, statin, and aspirin.